Biogen

News

Reuters - 3 days ago

US FDA approves injectable version of Roche's multiple sclerosis therapy

UPDATE 1-US FDA approves injectable version of Roche's multiple sclerosis therapy Adds price and availability in paragraph 4 Sept 13 (Reuters) - The U.S. Food and Drug Administration on Friday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The subcutaneous or under-the-skin therapy called Ocrevus Zunovo has the potential to expand treatment options to centers unable to administer the IV version.

Reuters - 3 days ago

US FDA approves injectable version of Roche's multiple sclerosis therapy

US FDA approves injectable version of Roche's multiple sclerosis therapy Sept 13 (Reuters) - The U.S. Food and Drug Administration on Friday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The subcutaneous or under-the-skin therapy called Ocrevus Zunovo has the potential to expand treatment options to centers unable to administer the IV version.

Reuters - 4 days ago

US FDA approves injectable version of Roche's multiple sclerosis therapy

UPDATE 1-US FDA approves injectable version of Roche's multiple sclerosis therapy Adds background throughout Sept 12 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The therapy is already approved as an infusion or IV therapy for multiple sclerosis, which is given twice a year, under the brand name Ocrevus.

Reuters - 4 days ago

US FDA approves injectable version of Roche's multiple sclerosis therapy

Reuters - 4 days ago

Biogen Board Appoints Two New Independent Directors

BRIEF-Biogen Board Appoints Two New Independent Directors Sept 12 (Reuters) - Biogen Inc BIIB.O : BIOGEN BOARD APPOINTS TWO NEW INDEPENDENT DIRECTORS BIOGEN INC - APPOINTS LLOYD MINOR AND MENELAS PANGALOS AS INDEPENDENT DIRECTORS Source text for Eikon: ID:nGNX3jZhPK Further company coverage: BIIB.O

Reuters - 5 days ago

Bio-Thera Solutions And Biogen Publish Phase 3 Clinical Trial Data For TOFIDENCE

BRIEF-Bio-Thera Solutions And Biogen Publish Phase 3 Clinical Trial Data For TOFIDENCE Sept 11 (Reuters) - Bio-Thera Solutions Ltd 688177.SS : BIO-THERA SOLUTIONS AND BIOGEN PUBLISH PHASE 3 CLINICAL TRIAL DATA FOR TOFIDENCE™ BIO-THERA SOLUTIONS: COMPARABLE CLINICAL EFFICACY, SAFETY IN TREATMENT PERIOD 2 IS MAINTAINED AFTER SWITCH FROM REFERENCE T

Reuters - 6 days ago

Ionis Pharma falls on pricing $500 mln stock offering

BUZZ-Ionis Pharma falls on pricing $500 mln stock offering ** Ionis Pharmaceuticals IONS.O shares down 7.5% at $44.71 premarket after co secures equity raise ** Co late Mon announced 11.5 mln shares at $43.50 for ~$500.3 mln gross proceeds with Morgan Stanley and Goldman Sachs as jt bookrunners ** Offering price represents 10% discount to stock's last sale ** Co plans to use net proceeds to fund independent commercial launches, late-stage clinical/earlier pipeline programs, R&D, and for other pu

Reuters - 1 week ago

Ionis Pharma drops on $500 mln stock offering plans

BUZZ-Ionis Pharma drops on $500 mln stock offering plans ** Shares of Ionis Pharmaceuticals IONS.O down 7.6% at $44.64 post-market as co seeks equity raise ** Co announces $500 mln stock offering with Morgan Stanley and Goldman Sachs as jt bookrunners ** It plans to use net proceeds to fund independent commercial launches, late-stage clinical/earlier pipeline programs, R&D, and other general purposes ** Last week, Biogen BIIB.O /IONS announced higher dose Spinraza regimen met primary endpoint in

Reuters - 2 weeks ago

What to Watch in the Day Ahead - Wednesday, September 4

What to Watch in the Day Ahead - Wednesday, September 4 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT U.S. investors will look forward to the Labor Department's Job Openings and Labor Turnover Survey, or JOLTS report.

Reuters - 4 weeks ago

U.S. STOCKS NetEase, Wolfspeed, B. Riley

BUZZ-U.S. STOCKS ON THE MOVE-NetEase, Wolfspeed, B. Riley Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes fell in volatile trading on Thursday, as rising Treasury yields pressured stocks ahead of Federal Reserve Chair Jerome Powell's speech at Jackson Hole that could offer clues on the possibility of a rate cut next month.

Reuters - 4 weeks ago

U.S. STOCKS Evogene, Stryker, Opera

BUZZ-U.S. STOCKS ON THE MOVE-Evogene, Stryker, Opera Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes fell in volatile trading on Thursday, as rising Treasury yields pressured stocks ahead of Federal Reserve Chair Jerome Powell's speech at Jackson Hole that could offer clues on the possibility of a rate cut next month.

Reuters - 4 weeks ago

Biogen falls after new Alzheimer's drug deemed costly by UK pricing watchdog

BUZZ-Biogen falls after new Alzheimer's drug deemed costly by UK pricing watchdog ** Shares of Biogen BIIB.O fall 1.3% to $203.45 ** UK health regulator has approved BIIB and partner Eisai's 4523.T drug Leqembi, making it the first treatment for Alzheimer's disease licensed for use in the country ** However, the UK cost effectiveness body, the Nati

Reuters - 4 weeks ago

New Alzheimer's drug deemed too costly for UK's state-run health service

UPDATE 5-New Alzheimer's drug deemed too costly for UK's state-run health service Eisai-Biogen drug first treatment to slow Alzheimer's course UK draft guidance on cost a blow after slow take-up in U.S. Adds Biogen shares in paragraph 10 and analyst comment in paragraph 19 By Maggie Fick Aug 22 (Reuters) - Alzheimer's patients in Britain's state-run health service are unlikely to get access to Eisai 4523.T and Biogen's BIIB.O new Leqembi drug, after it was approved on Thursday by the country's r

Reuters - 4 weeks ago

NHS Says Awaiting Final Decision From NICE To Determine If Lecanemab Should Be Offered By NHS In England

BRIEF-NHS Says Awaiting Final Decision From NICE To Determine If Lecanemab Should Be Offered By NHS In England Aug 22 (Reuters) - NHS: NHS-AWAITS FINAL DECISION FROM NICE FOR CLINICAL BENEFITS, COST-EFFECTIVENESS OF LECANEMAB TO DETERMINE IF IT SHOULD BE OFFERED BY NHS IN ENGLAND

Reuters - 4 weeks ago

Biogen Says Eisai Working With NICE, SMC, NHS To Make Alzheimer's Drug Available As Soon As Possible

BRIEF-Biogen Says Eisai Working With NICE, SMC, NHS To Make Alzheimer's Drug Available As Soon As Possible Aug 22 (Reuters) - BIOGEN: EISAI WORKING WITH NICE, SMC AND NHS TO MAKE THIS MEDICINE AVAILABLE TO ELIGIBLE PEOPLE LIVING WITH EARLY AD AS SOON AS POSSIBLE Source text for Eikon: ID:nPn2g0Jvha Further company coverage: 4523.T

Reuters - 4 weeks ago

UK patients unlikely to get access to Eisai-Biogen's Alzheimer's drug

UK patients unlikely to get access to Eisai-Biogen's Alzheimer's drug Aug 22 (Reuters) - Alzheimer's patients in Britain's state-run health service is unlikely to get access to Eisai 4523.T and Biogen's BIIB.O new Leqembi drug, after it was approved by the country's regulator but deemed too expensive for wide use on Thursday. Reporting by Maggie Fi

Reuters - 4 weeks ago

UK's MHRA Approves Eisai-Biogen's Alzheimer's drug

BRIEF-UK's MHRA Approves Eisai-Biogen's Alzheimer's drug Aug 22 (Reuters) - UK'S MHRA: LECANEMAB LICENSED FOR ADULT PATIENTS IN EARLY STAGES OF ALZHEIMER’S DISEASE UK'S MHRA: TOGETHER WITH CONDITIONS OF LICENCE APPROVAL, APPROPRIATE REGULATORY STANDARDS FOR LECANEMAB HAVE BEEN MET Further company coverage: 4523.T

Reuters - 4 weeks ago

UK's NICE Says Benefits Of Alzheimer’S Treatment Lecanemab Too Small To Justify Cost To NHS

BRIEF-UK's NICE Says Benefits Of Alzheimer’S Treatment Lecanemab Too Small To Justify Cost To NHS Aug 22 (Reuters) - UK'S NICE: UK'S NICE: BENEFITS OF ALZHEIMER’S TREATMENT LECANEMAB ARE TOO SMALL TO JUSTIFY COST TO THE NHS UK'S NICE: ISSUED DRAFT GUIDANCE FOR CONSULTATION NOT RECOMMENDING LECANEMAB FOR USE ON NHS AS IT IS NOT COST EFFECTIVE US

Reuters - 4 weeks ago

Alzheimer's drug from Eisai and Biogen to get approval in The Telegraph

MEDIA-Alzheimer's drug from Eisai and Biogen to get approval in UK - The Telegraph -- Source link: https://tinyurl.com/2xj9ac4e -- Note: Reuters has not verified this story and does not vouch for its accuracy

Reuters - 1 month ago

Incyte's blood cancer drug succeeds late-stage trial

Incyte's blood cancer drug succeeds late-stage trial Aug 15 (Reuters) - Incyte INCY.O said on Thursday its drug met the main goal in a late-stage trial evaluating it in patients with a form of blood cancer. The company said its drug Monjuvi, combined with Bristol Myers Squibb's BMY.N drug, Revlimid, and Biogen's BIIB.O Rituxan achieved progression free survival in patients with follicular lymphoma (FL), when compared to Rituxan and Revlimid alone.

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Biogen

News

Conditions

Popular Assets

XM Live Chat